Editas Medicine’s shares fell by nearly 4% afterhours when Allergan’s new owner AbbVie decided to end a deal originally penned under its buyout with the gene-editing biotech.
The pact between Editas and Allergan was penned back in the spring of 2017, with the biotech getting $90 million for a CRISPR research pact that focused on ocular disorders.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,